/ WHAT YOU WILL RECEIVE
Real photographs of your peptides — boxed, lot-labeled, and shipped in plain unmarked packaging from our partner research lab.
More batch photos and lab footage coming soon.
PEPTIDE SEQUENCE · STRUCTURE NOTE
Y-Aib-QGTFTSDYSILLDKKAQ-Aib-AFIEYLLEGGPSSGAPPPS-NH2
Triple agonist (GLP-1 / GIP / Glucagon) with C20 fatty acid chain conjugated to Lys.
⏱ HALF-LIFE · PHARMACOKINETIC PROFILE
Triple agonist (GLP-1 / GIP / Glucagon)
5–7 days
Long-acting backbone with C20 fatty-acid chain — designed for once-weekly research dosing.
GLP-1s · RESEARCH GRADE
Retatrutide
60mg · Lyophilized Vial · Triple Agonist
SELECT DOSAGE
Sold Out
This variant is temporarily unavailable — drop your email below to get notified.
Triple agonist (GLP-1 / GIP / Glucagon) — max-capacity 60mg flagship research vial.
UNIT PRICE
$185 USD
≈ CA$259
Reconstitution required
This compound requires bacteriostatic water for reconstitution. Don't forget to add a 10mL vial of BAC water to your order — available in Lab Supplies.
HOW LONG WILL IT LAST YOU?
Enter your research protocol and vial quantity — see exactly how many weeks your order covers.
Each 60mg vial lasts
30 weeks
Your 60mg vial lasts
30weeks
≈ 210 days · 30 doses per vial
FOR RESEARCH USE ONLY
Not for human consumption. Intended for laboratory and in-vitro research applications./ BUNDLE & SAVE · AGGRESSIVE PRICING
Stack up.
Save big.
Flat bundle prices on 60mg Retatrutide. Discounts apply automatically at the cart.
Save 10% · Mix & match any dosage
Save 16% · Most researchers choose this
Save 24% · Max-research economy
/ RESEARCH INFORMATION · STANDARDIZED PROFILE
Full breakdown.
Every compound on Helixora ships with a consistent six-section research profile so you can compare and reference quickly.
Overview & Classification
Retatrutide is a synthetic 39-residue triple-incretin analog (GLP-1 / GIP / glucagon receptor agonist) under late-stage research as the next-generation incretin therapeutic.
Type
Triple-agonist peptide
Derivation
Synthetic — solid-phase peptide synthesis with C20 fatty-diacid conjugation for albumin binding.
Structural
39-aa modified GIP backbone with substitutions enabling balanced activity at GLP-1R, GIPR, and GCGR.
Mechanism of Action
- ·Activates GLP-1 receptors → enhanced glucose-dependent insulin secretion + delayed gastric emptying
- ·Activates GIP receptors → potentiated insulinotropic effect + adipose-tissue signaling
- ·Activates glucagon receptors → upregulated hepatic energy expenditure and lipid oxidation
- ·Triple synergy produces appetite-suppression and energy-expenditure effects exceeding single- or dual-agonists
Research Highlights
- ·Phase 2 weight-loss trials reported sustained reductions in body weight beyond GLP-1-monotherapy baselines
- ·Improved glycemic markers in T2D research populations
- ·Notable adipose-tissue lipolysis observed at higher dose tiers
- ·Tolerability profile broadly comparable to other long-acting incretins at equivalent escalation
Research Usage Parameters
- ·Common research dose range: 2–12mg subcutaneous, once weekly
- ·Typical titration: start 2mg/wk, escalate every 4 weeks
- ·Research duration: 24–48 week protocols common
Pharmacological Profile
Half-life
~6 days (once-weekly dosing supported)
Absorption
Subcutaneous absorption; albumin-binding extends serum residency
Distribution
Predominantly extracellular — minimal CNS penetration
Safety Profile
- ·GI: nausea, decreased appetite, delayed gastric emptying — dose-dependent
- ·Avoid with personal/family history of medullary thyroid carcinoma or MEN2 syndromes (research caution)
- ·Hypoglycemia risk low as monotherapy; elevates with concomitant insulin or sulfonylurea
- ·Always follow institutional protocols and IRB/IACUC requirements
/ RESEARCH DOSSIER